FASEB J. Uncover Your Biological Pathway
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MAURICE, P.
Right arrow Articles by FAUVEL-LAFEVE, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MAURICE, P.
Right arrow Articles by FAUVEL-LAFEVE, F.
(The FASEB Journal. 2004;18:1339-1347.)
© 2004 FASEB

Platelet adhesion and signaling induced by the octapeptide primary binding sequence (KOGEOGPK) from type III collagen

PASCAL MAURICE, CHANTAL LEGRAND and FRANÇOISE FAUVEL-LAFEVE1

U553 INSERM: Hémostase, Endothélium et Angiogénèse, Institut d’Hématologie, Université Paris VII-Denis Diderot, IFR Saint-Louis, Hôpital Saint-Louis, Paris Cedex, France

1Correspondence: U 553 INSERM, Hôpital Saint-Louis, 1 Avenue Claude Vellefaux, 75475 Paris-cedex 10, France. E-mail: f.lafeve{at}chu-stlouis.fr


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Platelet adhesion to vascular collagens is an essential step in the initiation of hemostasis and thrombosis. Several platelet receptors interact with type I and type III collagens, including GP Ia/IIa and GP VI. We recently described a new platelet receptor (TIIICBP) specific for a type III collagen-related primary binding sequence, the KOGEOGPK octapeptide. Here, we characterize platelet adhesion to the immobilized octapeptide and demonstrate that this adhesion 1) is Ca2+ and Mg2+ independent, suggesting a noninvolvement of GP Ia/IIa; 2) is not inhibited by an antibody against GP VI; and 3) triggers platelet protein tyrosine phosphorylation. Whereas TXA2 has minimal effects, released ADP via only P2Y12 potentiates platelet adhesion to the octapeptide. Octapeptide-induced platelet adhesion triggers platelet signaling through tyrosine phosphorylation of the 68 kDa subunit of TIIICBP, Syk, PLCgamma2, and FAK. Tyrosine phosphorylation of the FcR gamma-chain and LAT is also observed but to a lesser extent than with type III collagen, suggesting the requirement of GP VI for full tyrosine phosphorylation of FcR gamma-chain and LAT. The present study provides evidence for a critical role for the type III collagen-related KOGEOGPK octapeptide in mediating platelet adhesion and signaling, and consequently in platelet-collagen interactions.—Maurice, P., Legrand, C., Fauvel-Lafève, F. Platelet adhesion and signaling induced by the octapeptide primary binding sequence (KOGEOGPK) from type III collagen.


Key Words: platelet aggregation • glycoprotein • platelet-collagen interaction


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
TYPE I AND TYPE III COLLAGENS, exposed at sites of vascular injury, play a critical role in hemostasis and thrombosis (1) . Platelet-collagen interactions involve multiple platelet membrane receptors that bind directly or indirectly to multiple sites on different collagen fibers. The two principal platelet receptors known to directly interact with collagen are glycoprotein (GP) Ia/IIa ({alpha}2ß1 integrin) (2) and GP VI (p62) (3) .

Among the platelet reacting sites on collagen, the GPO motifs, making up ~10% of type I and type III collagen (4) , constitute binding sites for the GP VI receptor. GP Ia/IIa possesses multiple binding domains within type I collagen (5 , 6) and type III collagen (7) . The participation of GP Ia/IIa in type I collagen-induced platelet adhesion is well recognized, but its contribution to platelet adhesion to type III collagen is controversial and depends on the conformation of type III collagen (8 , 9) . Within type III collagen, the {alpha}1(III)-CB4 fragment was shown to be a highly reactive site for platelets (5) containing GP Ia/IIa (7) and vWF binding sites (10) . We previously demonstrated the existence of another platelet reactive site within this CB4 fragment from type III collagen corresponding to the octapeptide sequence KOGEOGPK (11) . When immobilized, this isolated octapeptide induced platelet adhesion in both static and flow conditions (12) but inhibited type III collagen-induced platelet aggregation (13) . The platelet receptor for this octapeptide has been identified as a new platelet receptor for collagen and called type III collagen binding protein (TIIICBP) (12) . This receptor, a 68–72 kDa protein doublet, was shown to be a primary platelet receptor for type III collagen since blocking TIIICBP by the octapeptide or monoclonal antibodies prevented platelet contact and spreading on type III collagen under static and flow conditions. Moreover, the blockade of TIIICBP inhibited platelet adhesion and aggregation induced by type III collagen but not by type I collagen (14) .

Interaction of platelets with collagen triggers platelet activation and signaling. Collagen binding to GP VI, a member of the immunoglobulin superfamily (15 16 17) noncovalently coupled with the Fc receptor (FcR) {gamma}-chain (18 , 19) , triggers phosphorylation of the FcR {gamma}-chain by Src family tyrosine kinases (20 , 21) and leads to the recruitment and activation of Syk (22) , resulting in PLC{gamma}2 activation. Several adaptor proteins have been shown to be critical in response to activation of GP VI, most notably the linker for activation of T cells (LAT) (23) . Signaling by GP Ia/IIa was controversial until the recent studies by Inoue et al. (24 , 25) demonstrating GP Ia/IIa-dependent tyrosine phosphorylation of many signaling proteins including Syk, PLC{gamma}2, and FAK but not LAT.

In the present study, we have focused on platelet adhesion and signaling induced by the immobilized KOGEOGPK octapeptide. We demonstrate that platelet adhesion to the immobilized octapeptide is independent of Ca2+ and Mg2+ cations and independent of GP VI. Moreover, we show that octapeptide-mediated platelet adhesion is potentiated by released ADP (Gi-coupled pathways), with evidence for very minor participation of TXA2. We demonstrate for the first time that platelet adhesion to a primary binding site from type III collagen triggers a signaling pathway similar to the one induced by GP VI through tyrosine phosphorylation of the FcR {gamma}-chain, LAT, Syk, PLC{gamma}2, and FAK. TIIICBP is phosphorylated after octapeptide-induced platelet adhesion and constitutively associated with the FcR {gamma}-chain and LAT but not with GPVI. However, our results suggest a potential cooperation between TIIICBP and GPVI during GPVI-mediated platelet activation.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Materials
Acid-soluble type I and pepsin extracted type III collagens were purified from calf skin as described by Fujii and Kühn (26) . The purity of collagen preparations was assessed by SDS-PAGE chromatography under reducing and nonreducing conditions. The KOGEOGPK octapeptide was synthesized by Genosphère (Paris, France). The biotinylated-octapeptide was prepared in our laboratory. Briefly, the octapeptide was preincubated with EZ-LinkTM sulfo-NHS-LC-biotin (Pierce, Rockford, IL, USA) and biotinylated-octapeptide was separated from free biotin by gel filtration using a Peptide-75 column (Amersham Pharmacia Biotech, Buckinghamshire, UK). Bovine albumin fraction V, apyrase, RGDS, Triton X-100, and p-nitrophenylphosphate were from Sigma (St. Louis, MO, USA). AR-C69931MX was a generous gift from AstraZeneca (Loughborough, UK). BCATM Protein Assay kit and RestoreTM Western Blot Stripping Buffer were purchased from Pierce. Protein G SepharoseTM 4 fast flow was from Amersham Pharmacia Biotech. Rabbit polyclonal anti-FcR {gamma}-chain, anti-LAT antibodies, and mouse monoclonal antibody against phosphotyrosine (4G10) were purchased from Upstate Biotechnology (Lake Placid, NY, USA). Mouse monoclonal anti-Syk antibody was obtained from Chemicon International (Temecula, CA, USA). Rabbit polyclonal anti-PLC{gamma}2 and anti-FAK antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The convulxin (cvx) and the 3J24.2 and 9O12.2 monoclonal antibodies against GP VI were kindly donated by Dr. Martine Jandrot-Perrus (Inserm, Hôpital Bichat, Paris, France) and the 7F4 monoclonal antibody against TIIICBP was produced by our laboratory as described previously (14) . The collagen-related peptides (CRP) were obtained from Dr. Farndale (Cambridge, UK).

Platelet isolation
Blood was obtained from consenting healthy human donors and anticoagulated with acid-citrate-dextrose. Washed platelets were prepared as described previously (27) . After the last wash, platelets were resuspended into a pH 7.5 Tyrode’s buffer (137 mM NaCl, 2.7 mM KCl, 1.2 mM NaHCO3, 0.36 mM NaH2PO4, 2 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, 5.5 mM glucose) and adjusted to 2 x 108 platelets/mL.

Platelet adhesion assay
F96-MaxiSorp plates (Nunc, Naperville, IL, USA) were coated with 100 µL per well of either 0.1 mg/mL type I collagen, type III collagen, or octapeptide in 0.1 M phosphate buffer (pH 8.0) for 2 h at room temperature; 0.1% BSA was used as a negative control in separate wells. The wells were then washed three times with 0.1 M phosphate buffer (pH 8.0). Washed platelet (107/well) preparations were usually preincubated with 1 mM RGDS for 10 min at 37°C to block the GP IIb/IIIa functions (except for kinetic analysis, where the global washed platelet deposition was studied) and added to the wells for 1 h at room temperature. After three washes in Tyrode’s buffer, the number of adherent platelets was evaluated colorimetrically as described by Bellavite et al. (28) . The number of adherent platelets was ~15 to 21% of added platelets on both types of collagen or octapeptide and normalized at 100% adhesion (control) in each experiment.

Influence of divalent cations on platelet adhesion
For quantification of Ca2+ and Mg2+ effects on platelet adhesion to octapeptide, the number of adherent platelets was determined using washed platelets in a free MgCl2 and CaCl2 Tyrode’s buffer, in the same buffer containing 1 mM MgCl2 or 2 mM CaCl2, or both 1 mM MgCl2 and 2 mM CaCl2.

Involvement of GP VI in platelet adhesion
Platelet suspensions were pretreated with the 9O12.2 antibody for 5 min at 37°C before their addition to the microtiter wells.

Influence of generated TXA2 and ADP receptors on platelet adhesion
To determine the influence of generated TXA2 on platelet adhesion, washed platelets were preincubated for 1 min at 37°C with 5 µM of indomethacin (Sigma), a cycloxygenase inhibitor, before their addition to the microtiter wells. The importance of P2Y1 and P2Y12 on platelet adhesion to the octapeptide was evaluated using 111In-labeled platelets (27) pretreated for 10 min at 37°C with 100 µM of A3P5P (Sigma) or 10 µM of AR-C69931MX, respectively.

Platelet aggregation
Aggregation was monitored by measuring light transmission through a suspension of stirred washed platelets (2x108/mL) using a Beckman Chrono-Log aggregometer.

Immunoprecipitations
After 1 h adhesion, adherent platelets were lysed with a ice-cold lysis buffer containing 2% Triton X-100, a protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany), 2 mM sodium orthovanadate, and 10 mM sodium fluoride in free CaCl2 and MgCl2 Tyrode’s buffer. Platelet lysates were incubated for 30 min at 4°C under gentle end-over-end mixing. After incubation, platelet lysates were centrifuged at 12,000 g for 10 min to remove insoluble materials and protein concentration in supernatant was determined. Immunoprecitation of the FcR {gamma}-chain, LAT, Syk, PLC{gamma}2, and FAK was performed using protein G SepharoseTM and their corresponding antibodies. Immunoprecipitation of TIIICBP receptor was performed using the 7F4 monoclonal antibody against TIIICBP.

Immuno- and ligand blotting
Analysis of protein tyrosine phophorylation was performed on immunoprecipitates of whole cell lysates of adherent or resting platelets. The same protein concentration for each aliquot was resuspended in Laemmli buffer, heated at 100°C for 5 min and subjected to SDS-PAGE on 7.5% acrylamide or 4%-20% tricine gels. Proteins were transferred on a nitrocellulose membrane and probed with 4G10. After stripping, the membrane was first incubated with antibodies against the FcR {gamma}-chain, LAT, Syk, PLC{gamma}2 or FAK followed by HRP-labeled anti-mouse or -rabbit antibodies. In the case of TIIICBP, the membrane was first probed with biotinylated-octapeptide, followed by HRP-coupled streptavidin. Proteins were visualized by ECL.

Statistical evaluation
Results are reported as mean of three experiments run in triplicate ± SEM and statistical analysis were performed using the unpaired Student’s t test.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
In the static "adhesion" assay currently used, adhesion of washed platelets to purified collagen rapidly leads to GP IIb/IIIa activation and aggregation (29 , 30) . In fact, this assay measures platelet deposition to collagen. In a first step of experiments, we studied the time-dependent global washed platelet deposition to the immobilized octapeptide. Kinetic analysis revealed that platelet deposition to the immobilized octapeptide started immediately with a constant velocity for up to 60 min (Fig. 1 ). In contrast, platelet deposition to type III collagen exhibited a lag phase of ~10 min, then increased gradually. At 60 min, the number of deposited platelets on the octapeptide (18.8±2.6x105) or on type III collagen (14.8±5.8x105) was not significantly different. Platelet suspensions were next preincubated with 1 mM RGDS at a concentration that completely blocked collagen-induced platelet aggregation in stirred suspension (data not shown) to inhibit the GP IIb/IIIa participation in ligand binding, platelet aggregation, and avoid an overestimation of the adhesion rate. Under these conditions, the number of adherent platelets at 60 min was decreased by 33% on the octapeptide and by 37% on type III collagen.



View larger version (13K):
[in this window]
[in a new window]
  		Figure 1. Time course of platelet deposition to immobilized octapeptide and type III collagen. RGDS-untreated washed platelets (107 platelets/well) were added to microtiter wells coated with octapeptide (black curve) or type III collagen (hatched curve) for various times between 2 to 60 min at room temperature. Nonspecific deposition (NSD) at 60 min was measured into microtiter wells coated with BSA. After washing, the number of deposited platelets was measured using a colorimetric assay. Results are expressed as mean ± SEM (n=3).

Platelet adhesion to immobilized octapeptide
Platelet adhesion to octapeptide is Ca2+ and Mg2+ independent
GP Ia/IIa-mediated platelet adhesion to type I collagen has been shown to be dependent on Mg2+ cations (2) . To evaluate the importance of divalent cations in octapeptide-induced platelet adhesion, adhesion experiments were performed 1) in the presence of both 2 mM CaCl2 and 1 mM MgCl2 (considered as 100% adhesion), 2) in the presence of either CaCl2 or MgCl2, 3) in the absence of CaCl2 and MgCl2, and compared with type I and type III collagen-induced platelet adhesion. Contrary to type I collagen, platelet adhesion to immobilized octapeptide or type III collagen was independent of either Ca2+ or Mg2+ cations (Fig. 2 ), suggesting that GP Ia/IIa did not participate in octapeptide-induced platelet adhesion.



View larger version (22K):
[in this window]
[in a new window]
  		Figure 2. Effect of divalent cations on platelet adhesion to immobilized octapeptide. RGDS-treated washed platelets (107 platelets/well) were added for 60 min at room temperature to microtiter wells coated with octapeptide, type I, or type III collagen. Platelet adhesion was analyzed in the presence of 2 mM CaCl2 and 1 mM MgCl2 (black bars), in the absence of both cations (hatched bars), and in the presence of 1 mM MgCl2 (gray bars) or 2 mM CaCl2 (white bars). After washing, the number of adherent platelets was measured using a colorimetric assay. Results are expressed in % of adherent platelets compared with the control (black bars) and are expressed as mean ± SEM (n=3).

Platelet adhesion to octapeptide is GP VI independent
To look for an eventual participation of GP VI in platelet adhesion to the octapeptide, we used the recently described 9O12.2 antibody against GP VI (31) . As shown in Fig. 3 , preincubation of platelets with 20 µg/mL 9O12.2 had no effect on platelet adhesion to octapeptide whereas 9O12.2 significantly decreased platelet adhesion to type III collagen by 30 ± 3%.



View larger version (11K):
[in this window]
[in a new window]
  		Figure 3. Platelet adhesion to immobilized octapeptide is independent of GP VI. Washed platelets (2x107 platelets/well) were preincubated with the 9O12.2 antibody against GP VI (white bars) or not (black bars) and added for 15 min at room temperature to microtiter wells coated with octapeptide or type III collagen. After washing, the number of adherent platelets was measured using a colorimetric assay. Results are expressed in % of adherent platelets compared with the control (black bars) and expressed as mean ± SEM (n=3).

Effects of ADP and TXA2 on platelet adhesion to octapeptide
The involvement of ADP receptors P2Y1 and P2Y12 in platelet adhesion to the octapeptide was next determined by using the P2Y1 antagonist A3P5P (100 µM) and the P2Y12 inhibitor AR-C69931MX (10 µM), at concentrations currently used in the literature (32 , 33) . A3P5P had no effect on platelet adhesion to the octapeptide whereas a partial inhibition (26±6%) was observed in the presence of AR-C69931MX. In contrast, platelet adhesion to type III collagen was significantly decreased by 41 ± 7% and 76 ± 3% using A3P5P and AR-C69931MX, respectively (Fig. 4 A). The effect of generated TXA2 on platelet adhesion was determined using the cycloxygenase inhibitor indomethacin (Fig. 4B ). At 5 µM, indomethacin slightly but significantly decreased platelet adhesion to octapeptide (9±2%) and type III collagen (20±1%), indicating that TXA2 contributes minimally to platelet adhesion to the octapeptide.



View larger version (16K):
[in this window]
[in a new window]
  		Figure 4. Effect of ADP receptor antagonists and cycloxygenase inhibitor on platelet adhesion to immobilized octapeptide. A) RGDS-treated washed platelets labeled with 111Indium (107 platelets/well) were incubated with 100 µM A3P5P (gray bars), 10 µM AR-C69931MX (white bars), or buffer (black bars) before their addition, for 60 min at room temperature, to microtiter wells coated with octapeptide or type III collagen. B) RGDS-treated washed platelets (107 platelets/well) were incubated with 5 µM indomethacine (white bars) or buffer (black bars) and added, for 60 min at room temperature, to microtiter wells coated with octapeptide or type III collagen. Results are expressed in % of adherent platelets compared with the control (black bars) and are expressed as mean ± SEM (n=3).

Platelet signaling induced by the octapeptide
Kinetics of protein phosphorylation
The ability of the octapeptide to induce platelet protein tyrosine phosphorylation was investigated. After 1 h adhesion, the tyrosine phosphorylation profiles induced by platelet deposition to the octapeptide or to type III collagen were similar and blocking GP IIb/IIIa by 1 mM RGDS slightly increased the whole phosphorylation (Fig. 5 A). Kinetic analysis revealed that tyrosine phosphorylation induced by platelet adhesion to the octapeptide is a rapid phenomenon (Fig. 5B ), as many phosphorylated bands were observed after only 1 min adhesion. Because platelets did not significantly adhere to type III collagen before 10 min, it was not possible to compare their phosphorylation state at early times.



View larger version (71K):
[in this window]
[in a new window]
  		Figure 5. Platelet adhesion to immobilized octapeptide triggers a time-dependent increase in protein tyrosine phosphorylation. A) Samples of whole cell lysates from buffer (lanes 1 and 3) or RGDS (lanes 2 and 4) -treated washed platelets adherent to either octapeptide (8P) or type III collagen (TIII) for 60 min or unstimulated platelets (C) were separated by SDS-PAGE on a 7.5% acrylamide gel. Proteins were transferred to a nitrocellulose membrane and probed with the anti-phosphotyrosine antibody 4G10. B) Samples of whole cell lysates from platelets adherent to octapeptide for various times between 1 to 9 min or unstimulated platelets (C) were separated by SDS-PAGE on a 7.5% acrylamide gel. Proteins were transferred to a nitrocellulose membrane and probed with the anti-phosphotyrosine antibody 4G10. Molecular masses of some tyrosine phosphorylated protein bands are shown on the right side.

Immunoprecipitation of signaling proteins
To check for phosphorylation of TIIICBP, the receptor for octapeptide, TIIICBP, was immunoprecipitated from lysates of platelets adherent to either immobilized octapeptide or type III collagen, using the 7F4 monoclonal antibody. As shown in Fig. 6 A, platelet adhesion to the octapeptide or to type III collagen induced tyrosine phosphorylation of the 68 kDa subunit of TIIICBP.



View larger version (56K):
[in this window]
[in a new window]
  		Figure 6. Tyrosine phosphorylation of TIIICBP and signaling proteins in platelet adherent to immobilized octapeptide. Platelet adherent to either octapeptide (8P) or type III collagen (TIII) for 60 min or unstimulated platelets(C) were lysed and TIIICBP (A, D), the FcR {gamma}-chain (B), LAT (C), Syk (E), PLC{gamma}2 (F), or FAK (G) were immunoprecipitated. For each experiment, the same amount of platelet proteins was separated by SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was probed with the anti-phosphotyrosine antibody 4G10 (upper) and subsequently stripped and reprobed with biotinylated octapeptide (A, D), or anti-FcR {gamma}-chain (B, D), -LAT (C, D), -Syk (E), -PLC{gamma}2 (F), or -FAK (G) antibodies (lower).

Participation of the FcR {gamma}-chain and LAT in octapeptide-mediated platelet signaling was evaluated. We observed phosphorylation of the FcR {gamma}-chain and LAT after platelet adhesion to the octapeptide. However, the intensity of their phosphorylation was weaker than for type III collagen-adherent platelets (Fig. 6B, C ). The FcR {gamma}-chain and LAT coimmunoprecipitated in TIIICBP immunoprecipitates, even in nonactivated platelets (Fig. 6D ). A coimmunoprecipitation of GP VI with TIIICBP was not observed in our conditions (not shown).

Syk and PLC{gamma}2 were also immunoprecipitated from platelets adherent to either immobilized octapeptide or type III collagen in order to study their participation in platelet signaling. Figure 6E, F shows that platelet adhesion to immobilized octapeptide, as to type III collagen, strongly promoted tyrosine phosphorylation of Syk and PLC{gamma}2 even in the presence of RGDS (not shown). PLC{gamma}2 coimmunoprecipitated in Syk immunoprecipitates and vice versa, demonstrating association of these two signaling molecules in octapeptide-mediated platelet activation.

Immunoprecipitation of FAK
Focal adhesion complexes connect membrane integrins to actin cytoskeleton and constitute a starting point for signaling in platelets. The nonreceptor tyrosine kinase FAK is one of the more representative proteins present in focal adhesion complexes prone to be tyrosine phosphorylated during platelet activation (34 , 35) . We therefore tested the ability of the octapeptide to induce formation of focal adhesion complexes during platelet adhesion. As observed in Fig. 6G , FAK was tyrosine phosphorylated in platelets adherent to immobilized octapeptide or type III collagen. This phosphorylation was also observed in the presence of RGDS (not shown).

Cooperation between GP VI and TIIICBP during GP VI-induced platelet aggregation
Although an association of GP VI with TIIICBP was not observed during immunoprecipitation experiments, we have studied the effects of the 7F4 monoclonal antibody or the octapeptide on platelet aggregation induced by two agonists of GP VI: convulxin and CRP. Pretreatment of platelets with 7F4 (50 µg/mL) or the octapeptide (0.5 mM) decreased by respectively 36% and 45% platelet aggregation induced by 150 pM convulxin (Fig. 7 A) and by respectively 44% and 32% platelet aggregation induced by 75 ng CRP (Fig. 7B ). These effects were specific since type III collagen-mediated platelet aggregation was completely inhibited by 7F4 or the octapeptide as described previously (12 , 14) , whereas thrombin-mediated platelet aggregation, independent of TIIICBP, was not affected (not shown).



View larger version (19K):
[in this window]
[in a new window]
  		Figure 7. Effect of TIIICBP inhibition on platelet aggregation induced by convulxin and CRP. Washed human platelets (2x108/mL) were pretreated with buffer (control), anti-TIIICBP monoclonal antibody 7F4 (50 µg/mL) or octapeptide (0.5 mM) for 5 min at 37°C. Platelet aggregation was induced by 150 pM convulxin (A) or 75 ng CRP (B).


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In this study, we demonstrate a direct role for the primary binding sequence from type III collagen, the KOGEOGPK octapeptide, in promoting platelet adhesion and subsequent signaling. This octapeptide recognizes a receptor for type III collagen on platelets (TIIICBP). Blockade of TIIICBP by the octapeptide or monoclonal antibodies inhibits platelet adhesion to type III collagen and subendothelium in either static or flow conditions (14) . Since the octapeptide also inhibited platelet contact with type III collagen in the absence of platelet activation (14) , platelet-octapeptide interaction constitutes an early event preceding full adhesion and activation to collagen and subendothelium.

We first investigated platelet deposition to immobilized octapeptide in static conditions. When performed in the absence of aggregation inhibitor, the model used is a mixture of platelet contact, adhesion, and aggregation. Whereas platelet deposition mediated by the immobilized octapeptide occurred rapidly, deposition to type III collagen presented a lag phase of ~10 min, probably corresponding to the time needed for primary interactions mediated in part by octapeptide sequences present in lesser number within the collagen molecule. At 60 min, the tyrosine phosphorylation pattern induced by platelet deposition to the immobilized octapeptide was similar to the one obtained with type III collagen, suggesting activation of similar signaling pathways. When aggregation was blocked by RGDS, a slight increase in the whole phosphorylation was observed, possibly due to inhibition of the GP IIb/IIIa-dependent dephosphorylation step, as described recently by Francischetti et al. (36) . This dephosphorylation step was shown to be dependent of platelet aggregation and inhibited by RGDS (37) .

To characterize platelet adhesion to the immobilized octapeptide and the associated signaling events, subsequent experiments were performed in the presence of RGDS. Our results demonstrate that platelet adhesion to immobilized octapeptide is independent of extracellular Ca2+ and Mg2+, providing evidence that GP Ia/IIa, which requires divalent cations to function (2) , does not contribute to platelet adhesion to the immobilized octapeptide and that TIIICBP does not belong to the integrin family. This confirms our previous results on the failure of anti-GP Ia/IIa antibody (6F1) to inhibit platelet adhesion to the immobilized octapeptide (12) .

The immobilized octapeptide contains the three amino acids that could form GPO motifs able to react with GP VI. However, using the 9O12.2 antibody against GP VI (31) , we demonstrated that platelet adhesion to the octapeptide is independent of GP VI; thus, it is unlikely that immobilized octapeptide forms GPO motifs in the right conformation recognized by GP VI.

Nakamura et al. (38) have proposed a direct link between GP VI and generation of TXA2 during platelet-collagen adhesive interactions and the necessity of the collagen polymeric fibrillar structure to induce generation of TXA2. Using indomethacin, an inhibitor of TXA2 generation, we show that the TXA2-dependent pathway plays a minor role in GP IIb/IIIa-independent platelet adhesion to type III collagen and is almost negligible for adhesion to the octapeptide. This is consistent with the report from Nakamura et al. (39) , who proposed that, during platelet adhesion to collagen, generated TXA2 was involved in the activation of GP IIb/IIIa and had a minimal effect on platelet adhesion and spreading.

Using inhibitors of the P2Y1 and P2Y12 ADP receptors (40) , we observed that released ADP was a potent cofactor of platelet adhesion to type III collagen. In contrast, platelet adhesion to the immobilized octapeptide was less sensitive to released ADP, as it was dependent only on the P2Y12 ADP receptor. Because the contact phase is an initial event in platelet-collagen interaction involving nonactivated platelets (8) , it is likely that platelet adhesion to the immobilized octapeptide is independent of secondary secreted agonists. Thereby, platelet interactions with octapeptide sequences could contribute to the ADP-independent residual adhesion to type III collagen. Moreover, the slight ADP-sensitive part of platelet adhesion to the immobilized octapeptide could be subsequent to the initial platelet contact mediated by TIIICBP and involve activation of a subset of additional TIIICBP or other receptors, leading to enhanced granule secretion and platelet recruitment. Until the recent revision of the two-step/two-site model by Nieswandt and Watson (4) , GP Ia/IIa was considered the main adhesive receptor for collagen, with GP VI principally involved in platelet activation and signaling (41 , 42) . This model now places GP VI in a central position in platelet-collagen interactions. GP Ia/IIa binding to collagen requires prior activation by intracellular signals generated by GP VI and is reinforced by released ADP and TXA2. Moreover, cooperation between GP VI and GP Ia/IIa is necessary to obtain the full platelet response to collagen in vitro (43) and for collagen-induced thrombus formation (44) . Nevertheless, our results raise the question of a GP VI requirement in initial events of platelet adhesion to type III collagen since a type III collagen-related sequence, the KOGEOGPK octapeptide, which is involved in the first steps (e.g., platelet contact and adhesion) of platelet interaction with collagen (12 , 14) , is able to promote platelet adhesion independently of GP VI.

In contrast to the whole collagen molecule, the octapeptide is unable to promote platelet aggregation when presented in solution, but instead must be immobilized on a plastic surface to induce platelet activation and signaling, probably due to its monovalent structure. Using type II collagen-related CNBr peptides, Guidetti et al. (45) have proposed that the inability of CNBr peptides to induce platelet aggregation is due to their inability to form fibrils. Therefore, once immobilized, the octapeptide could promote multiple interactions and possibly oligomerization of TIIICBP, necessary to trigger platelet activation and signaling. Our present results demonstrate that, like the whole type III collagen molecule, the octapeptide sequence when immobilized triggers platelet activation and strong GP IIb/IIIa-independent tyrosine phosphorylation of Syk and PLC{gamma}2. Tyrosine phosphorylation of the FcR {gamma}-chain and the transmembrane adaptor LAT were observed but to a lesser extent than those induced by type III collagen, suggesting the likely contribution of GP VI for full phosphorylation of the FcR {gamma}-chain and LAT. In addition, this study demonstrates that TIIICBP associates with the FcR {gamma}-chain and LAT independent of platelet activation. Although GP VI-independent phosphorylation of the FcR {gamma}-chain and LAT has already been reported in platelets activated by vWF/ristocetin, vWF/botrocetin (46) or by peptides related to the carboxyl-terminal domain of thrombospondin-1 (47 , 48) , a cooperation between TIIICBP and GP VI could be considered in order to elicit full tyrosine phosphorylation of the FcR {gamma}-chain and LAT during platelet-collagen adhesive interactions. This potential cooperation between TIIICBP and GP VI is supported by the fact that TIIICBP participates in GP VI-induced platelet aggregation. This involvement of TIIICBP seems to be specific since it was observed with two different GP VI agonists, convulxin and CRP, and two different TIIICBP inhibitors, 7F4 and soluble octapeptide. A dual specificity of convulxin for another platelet receptor, native GP Ib, has been demonstrated in the recent study by Kanaji et al. (49) . This raises the question of a potential indirect contribution of GP Ib in the inhibitory effect of TIIICBP inhibitors on GP VI-induced platelet aggregation. However, since convulxin- and CRP-mediated platelet aggregations are decreased to a similar extent when blocking TIIICBP, an indirect contribution of GP Ib seems unlikely.

Platelet adhesion to the octapeptide also induces phosphorylation of TIIICBP. It remains to be determined whether phosphorylation of the TIIICBP receptor immediately follows its binding to the octapeptide sequence or results from subsequent events such as association of TIIICBP with other platelet receptors like GP VI. Once tyrosine phosphorylated, TIIICBP, in association with the FcR {gamma}-chain and/or LAT, could represent a docking site for other signaling proteins and for GP VI leading to cooperation between these two collagen receptors for subsequent tyrosine phosphorylation of the FcR {gamma}-chain, LAT, and downstream signaling proteins leading to full platelet activation. How this cooperation between GP VI and TIIICBP is carried out and the respective contribution of each receptor in signaling induced by platelet adhesion to type III collagen remains to be determined. Since TIIICBP is constitutively associated with the FcR {gamma}-chain, we postulate that the FcR {gamma}-chain could be the physical link between TIIICBP and GP VI during type III collagen-mediated platelet activation, as already demonstrated for GP Ib{alpha} and GP VI during activation by alboaggregin A, which binds to GP Ib{alpha} and GP VI (50) . After receptor stimulation, GP VI is recruited in specialized areas of the platelet membrane called "lipid rafts" in an FcR {gamma}-chain-dependent manner (51) . Inhibition of TIIICBP by 7F4 or soluble octapeptide could partially block this specific GP VI recruitment, resulting in a decrease of platelet aggregation.

Immunoprecipitation experiments have revealed the GP IIb/IIIa-independent tyrosine phosphorylation of FAK during octapeptide-induced platelet adhesion, suggesting the formation of focal adhesion complexes and a link between TIIICBP and the platelet cytoskeleton. However, a direct association between TIIICBP and proteins of focal adhesion complexes remains to be determined.

In conclusion, the present study demonstrates for the first time a critical role for the type III collagen-related primary binding sequence, the KOGEOGPK octapeptide, in mediating platelet adhesion independent of GP Ia/IIa and GP VI. Platelet adhesion to the immobilized octapeptide is able to trigger a signaling pathway similar to the one induced by type III collagen, as attested by tyrosine phosphorylation of key signaling proteins such as Syk, the FcR {gamma}-chain, LAT, PLC{gamma}2, FAK, and TIIICBP itself. We show that TIIICBP participates in GP VI-mediated platelet aggregation and postulate for a potential cooperation between TIIICBP and GP VI with the FcR {gamma}-chain as the physical link in the platelet membrane. Although the FcR {gamma}-chain and LAT are constitutively associated with TIIICBP, a physical interplay between TIIICBP and GP VI remains to be clarified. Platelet primary interactions with the octapeptide should then be considered for future research dealing with platelet-type III collagen adhesive interactions and thrombus formation in vivo. Interaction of platelets with the octapeptide may also explain why GP Ia/IIa or GP VI deficiency in mice has a relatively minor effect on bleeding time (52 , 53) .


   ACKNOWLEDGMENTS
 
We would like to thank Doctor Martine Jandrot-Perrus for supplying the 9O12.2 and the 3J24.2 monoclonal antibodies against GP VI, Professor Mony Frojmovic for thoughtful discussions and critical reading of the manuscript, and Mrs. Joelle Treton and l’Etablissement Français du Sang from Hôpital Saint-Louis, Paris, for blood collection. This work was supported by INSERM and the inter-regional program "Régulation de la matrice extracellulaire pathologique."

Received for publication October 29, 2003. Accepted for publication April 27, 2004.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Rauterberg, J, Jaeger, E, Althaus, M. (1993) Collagens in atherosclerotic vessel wall lesions. Curr. Top. Pathol. 87,163-192[Medline]
  2. Santoro, S. A. (1986) Identification of a 160,000 dalton platelet membrane protein that mediates the initial divalent cation-dependent adhesion of platelets to collagen. Cell 46,913-920[CrossRef][Medline]
  3. Sugiyama, T., Okuma, M., Ushikubi, F., Sensaki, S., Kanaji, K., Uchino, H. (1987) A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. Blood 69,1712-1720[Abstract/Free Full Text]
  4. Nieswandt, B., Watson, S. P. (2003) Platelet-collagen interaction: is GPVI the central receptor?. Blood 102,449-461[Abstract/Free Full Text]
  5. Morton, L. F., Peachey, A. R., Barnes, M. J. (1989) Platelet-reactive sites in collagens type I and type III. Evidence for separate adhesion and aggregatory sites. Biochem. J. 258,157-163[Medline]
  6. Staatz, W. D., Walsh, J. J., Santoro, S. A. (1997) The alpha 2 beta 1 integrin binds to the CB4 peptide of the alpha 2(I) collagen chain. Biochem. Mol. Biol. Int. 42,577-582[Medline]
  7. Barnes, M. J., Knight, C. G., Farndale, R. W. (1996) The use of collagen-based model peptides to investigate platelet-reactive sequences in collagen. Biopolymers 40,383-397[CrossRef][Medline]
  8. Monnet, E., Sizaret, P., Arbeille, B., Fauvel-Lafeve, F. (2000) Different role of platelet glycoprotein GP Ia/IIa in platelet contact and activation induced by type I and type III collagens. Thromb. Res. 98,423-433[CrossRef][Medline]
  9. Jarvis, G. E., Atkinson, B. T., Snell, D. C., Watson, S. P. (2002) Distinct roles of GPVI and integrin alpha(2)beta(1) in platelet shape change and aggregation induced by different collagens. Br. J. Pharmacol. 137,107-117[CrossRef][Medline]
  10. Verkleij, M. W., IJsseldijk, M. J., Heijnen-Snyder, G. J., Huizinga, E. G., Morton, L. F., Knight, C. G., Sixma, J. J., de Groot, P. G., Barnes, M. J. (1999) Adhesive domains in the collagen III fragment alpha1(III)CB4 that support alpha2beta1- and von Willebrand factor-mediated platelet adhesion under flow conditions. Thromb. Haemost. 82,1137-1144[Medline]
  11. Fauvel, F., Legrand, Y. J., Kuhn, K., Bentz, H., Fietzek, P. P., Caen, J. P. (1979) Platelet adhesion to type III collagen: involvement of a sequence of nine aminoacids from alpha 1 (III) CB4 peptide. Thromb. Res. 16,269-273[CrossRef][Medline]
  12. Monnet, E., Fauvel-Lafeve, F. (2000) A new platelet receptor specific to type III collagen. Type III collagen-binding protein. J. Biol. Chem. 275,10912-10917[Abstract/Free Full Text]
  13. Karniguian, A., Legrand, Y. J., Lefrancier, P., Caen, J. P. (1983) Effect of a collagen derived octapeptide on different steps of the platelet/collagen interaction. Thromb. Res. 32,593-604[CrossRef][Medline]
  14. Monnet, E., Depraetere, H., Legrand, C., Deckmyn, H., Fauvel-Lafeve, F. (2001) A monoclonal antibody to platelet type III collagen-binding protein (TIIICBP) binds to blood and vascular cells, and inhibits platelet vessel-wall interactions. Thromb. Haemost. 86,694-701[Medline]
  15. Clemetson, J. M., Polgar, J., Magnenat, E., Wells, T. N., Clemetson, K. J. (1999) The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcalphaR and the natural killer receptors. J. Biol. Chem. 274,29019-29024[Abstract/Free Full Text]
  16. Jandrot-Perrus, M., Busfield, S., Lagrue, A. H., Xiong, X., Debili, N., Chickering, T., Le Couedic, J. P., Goodearl, A., Dussault, B., Fraser, C., et al (2000) Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily. Blood 96,1798-1807[Abstract/Free Full Text]
  17. Miura, Y., Ohnuma, M., Jung, S. M., Moroi, M. (2000) Cloning and expression of the platelet-specific collagen receptor glycoprotein VI. Thromb. Res. 98,301-309[CrossRef][Medline]
  18. Gibbins, J. M., Okuma, M., Farndale, R., Barnes, M., Watson, S. P. (1997) Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain. FEBS Lett. 413,255-259[CrossRef][Medline]
  19. Tsuji, M., Ezumi, Y., Arai, M., Takayama, H. (1997) A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J. Biol. Chem. 272,23528-23531[Abstract/Free Full Text]
  20. Ezumi, Y., Shindoh, K., Tsuji, M., Takayama, H. (1998) Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets. J. Exp. Med. 188,267-276[Abstract/Free Full Text]
  21. Briddon, S. J., Watson, S. P. (1999) Evidence for the involvement of p59fyn and p53/56lyn in collagen receptor signaling in human platelets. Biochem. J. 338,203-209
  22. Poole, A., Gibbins, J. M., Turner, M., van Vugt, M. J., van de Winkel, J. G., Saito, T., Tybulewicz, V. L., Watson, S. P. (1997) The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J. 16,2333-2341[CrossRef][Medline]
  23. Judd, B. A., Myung, P. S., Obergfell, A., Myers, E. E., Cheng, A. M., Watson, S. P., Pear, W. S., Allman, D., Shattil, S. J., Koretzky, G. A. (2002) Differential requirement for LAT and SLP-76 in GPVI versus T cell receptor signaling. J. Exp. Med. 195,705-717[Abstract/Free Full Text]
  24. Inoue, K., Ozaki, Y., Satoh, K., Wu, Y., Yatomi, Y., Shin, Y., Morita, T. (1999) Signal transduction pathways mediated by glycoprotein Ia/IIa in human platelets: comparison with those of glycoprotein VI. Biochem. Biophys. Res. Commun. 256,114-120[CrossRef][Medline]
  25. Inoue, O., Suzuki-Inoue, K., Dean, W. L., Frampton, J., Watson, S. P. (2003) Integrin alpha2beta1 mediates outside-in regulation of platelet spreading on collagen through activation of Src kinases and PLCgamma2. J. Cell Biol. 160,769-780[Abstract/Free Full Text]
  26. Fujii, T., Kuhn, K. (1975) Isolation and characterization of pepsin-treated type III collagen from calf skin. Hoppe Seylers Z. Physiol. Chem. 356,1793-1801[Medline]
  27. Fauvel-Lafève, F., Meric, A., Arbeille, B., Tabaka, V., Legrand, Y. J. (1993) Spectrophotometric evaluation of the adhesion of blood platelets to collagen and microfibrils. Thromb. Res. 71,193-204[CrossRef][Medline]
  28. Bellavite, P., Andrioli, G., Guzzo, P., Arigliano, P., Chirumbolo, S., Manzato, F., Santonastaso, C. (1994) A colorimetric method for the measurement of platelet adhesion in microtiter plates. Anal. Biochem. 216,444-450[CrossRef][Medline]
  29. Moroi, M., Okuma, M., Jung, S. M. (1992) Platelet adhesion to collagen-coated wells: analysis of this complex process and a comparison with the adhesion to matrigel-coated wells. Biochim. Biophys. Acta 1137,1-9[Medline]
  30. Wu, C. C., Ko, F. N., Huang, T. F., Teng, C. M. (1996) Mechanisms-regulated platelet spreading after initial platelet contact with collagen. Biochem. Biophys. Res. Commun. 220,388-393[CrossRef][Medline]
  31. Lecut, C., Feeney, L. A., Kingsbury, G., Hopkins, J., Lanza, F., Gachet, C., Villeval, J. L., Jandrot-Perrus, M. (2003) Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived Fab fragments. J. Thromb. Haemost. 1,2653-2662[CrossRef][Medline]
  32. Atkinson, B. T., Stafford, M. J., Pears, C. J., Watson, S. P. (2001) Signaling events underlying platelet aggregation induced by the glycoprotein VI agonist convulxin. Eur. J. Biochem. 268,5242-5248[Medline]
  33. Nieswandt, B., Schulte, V., Zywietz, A., Gratacap, M. P., Offermanns, S. (2002) Costimulation of Gi- and G12/G13-mediated signaling pathways induces integrin alpha IIbbeta 3 activation in platelets. J. Biol. Chem. 277,39493-39498[Abstract/Free Full Text]
  34. Vuori, K. (1998) Integrin signaling: tyrosine phosphorylation events in focal adhesions. J. Membr. Biol. 165,191-199[CrossRef][Medline]
  35. Arderiu, G., Diaz-Ricart, M., Buckley, B., Escolar, G., Ordinas, A. (2002) Primary arrest of circulating platelets on collagen involves phosphorylation of Syk, cortactin and focal adhesion kinase: studies under flow conditions. Biochem. J. 364,65-71[Medline]
  36. Francischetti, I. M., Ghazaleh, F. A., Reis, R. A., Carlini, C. R., Guimaraes, J. A. (1998) Convulxin induces platelet activation by a tyrosine-kinase-dependent pathway and stimulates tyrosine phosphorylation of platelet proteins, including PLC gamma 2, independently of integrin alpha IIb beta 3. Arch. Biochem. Biophys. 353,239-250[CrossRef][Medline]
  37. Francischetti, I. M., Carlini, C. R., Guimaraes, J. A. (1998) cAMP does not inhibit convulxin-induced tyrosyl-phosphorylation of human platelet proteins, including PLCgamma2, but completely blocks the integrin alphaIIb beta3-dependent dephosphorylation step: comparisons with RGDS peptide, cytochalasin D, and phenylarsine oxide. Arch. Biochem. Biophys. 354,255-262[CrossRef][Medline]
  38. Nakamura, T., Jamieson, G. A., Okuma, M., Kambayashi, J., Tandon, N. N. (1998) Platelet adhesion to native type I collagen fibrils. Role of GPVI in divalent cation-dependent and -independent adhesion and thromboxane A2 generation. J. Biol. Chem. 273,4338-4344[Abstract/Free Full Text]
  39. Nakamura, T., Kambayashi, J., Okuma, M., Tandon, N. N. (1999) Activation of the GP IIb-IIIa complex induced by platelet adhesion to collagen is mediated by both alpha2beta1 integrin and GP VI. J. Biol. Chem. 274,11897-11903[Abstract/Free Full Text]
  40. Kunapuli, S. P., Dorsam, R. T., Kim, S., Quinton, T. M. (2003) Platelet purinergic receptors. Curr. Opin. Pharmacol. 3,175-180[CrossRef][Medline]
  41. Hers, I., Berlanga, O., Tiekstra, M. J., Kamiguti, A. S., Theakston, R. D., Watson, S. P. (2000) Evidence against a direct role of the integrin alpha2beta1 in collagen-induced tyrosine phosphorylation in human platelets. Eur. J. Biochem. 267,2088-2097[Medline]
  42. Verkleij, M. W., Morton, L. F., Knight, C. G., de Groot, P. G., Barnes, M. J., Sixma, J. J. (1998) Simple collagen-like peptides support platelet adhesion under static but not under flow conditions: interaction via alpha2 beta1 and von Willebrand factor with specific sequences in native collagen is a requirement to resist shear forces. Blood 91,3808-3816[Abstract/Free Full Text]
  43. Kamiguti, A. S., Theakston, R. D., Watson, S. P., Bon, C., Laing, G. D., Zuzel, M. (2000) Distinct contributions of glycoprotein VI and alpha(2)beta(1) integrin to the induction of platelet protein tyrosine phosphorylation and aggregation. Arch. Biochem. Biophys. 374,356-362[CrossRef][Medline]
  44. Kuijpers, M. J., Schulte, V., Bergmeier, W., Lindhout, T., Brakebusch, C., Offermanns, S., Fassler, R., Heemskerk, J. W., Nieswandt, B. (2003) Complementary roles of glycoprotein VI and alpha2beta1 integrin in collagen-induced thrombus formation in flowing whole blood ex vivo. FASEB J. 17,685-687[Abstract/Free Full Text]
  45. Guidetti, G. F., Greco, F., Bertoni, A., Giudici, C., Viola, M., Tenni, R., Tira, E. M., Balduini, C., Torti, M. (2003) Platelet interaction with CNBr peptides from type II collagen via integrin alpha2beta1. Biochim. Biophys. Acta 1640,43-51[Medline]
  46. Marshall, S. J., Asazuma, N., Best, D., Wonerow, P., Salmon, G., Andrews, R. K., Watson, S. P. (2002) Glycoprotein IIb-IIIa-dependent aggregation by glycoprotein Ibalpha is reinforced by a Src family kinase inhibitor (PP1)-sensitive signalling pathway. Biochem. J. 361,297-305[CrossRef][Medline]
  47. Tulasne, D., Judd, B. A., Johansen, M., Asazuma, N., Best, D., Brown, E. J., Kahn, M., Koretzky, G. A., Watson, S. P. (2001) C-terminal peptide of thrombospondin-1 induces platelet aggregation through the Fc receptor gamma-chain-associated signaling pathway and by agglutination. Blood 98,3346-3352[Abstract/Free Full Text]
  48. Trumel, C., Plantavid, M., Levy-Toledano, S., Ragab, A., Caen, J. P., Aguado, E., Malissen, B., Payrastre, B. (2003) Platelet aggregation induced by the C-terminal peptide of thrombospondin-1 requires the docking protein LAT but is largely independent of alphaIIb/beta3. J. Thromb. Haemost. 1,320-329[CrossRef][Medline]
  49. Kanaji, S., Kanaji, T., Furihata, K., Kato, K., Ware, J. L., Kunicki, T. J. (2003) Convulxin binds to native, human glycoprotein Ib alpha. J. Biol. Chem. 278,39452-39460[Abstract/Free Full Text]
  50. Falati, S., Edmead, C. E., Poole, A. W. (1999) Glycoprotein Ib-V-IX, a receptor for von Willebrand factor, couples physically and functionally to the Fc receptor gamma-chain, Fyn, and Lyn to activate human platelets. Blood 94,1648-1656[Abstract/Free Full Text]
  51. Locke, D., Chen, H., Liu, Y., Liu, C., Kahn, M. L. (2002) Lipid rafts orchestrate signaling by the platelet receptor glycoprotein VI. J. Biol. Chem. 277,18801-18809[Abstract/Free Full Text]
  52. Holtkotter, O., Nieswandt, B., Smyth, N., Muller, W., Hafner, M., Schulte, V., Krieg, T., Eckes, B. (2002) Integrin alpha 2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen. J. Biol. Chem. 277,10789-10794[Abstract/Free Full Text]
  53. Nieswandt, B., Schulte, V., Bergmeier, W., Mokhtari-Nejad, R., Rackebrandt, K., Cazenave, J. P., Ohlmann, P., Gachet, C., Zirngibl, H. (2001) Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J. Exp. Med. 193,459-469[Abstract/Free Full Text]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MAURICE, P.
Right arrow Articles by FAUVEL-LAFEVE, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MAURICE, P.
Right arrow Articles by FAUVEL-LAFEVE, F.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS